New drug could reduce need for infusions in nerve disorder
NCT ID NCT06537999
First seen Jun 24, 2026 · Last updated Aug 11, 2026 · Updated 3 times
Summary
This Phase 2 trial tests a drug called claseprubart (DNTH103) in 36 adults with multifocal motor neuropathy, a rare nerve condition that causes muscle weakness. Participants receive either the drug or a placebo for 15 weeks. The study looks at safety, how the drug works in the body, and whether it can delay the need for standard immunoglobulin therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Claseprubart (also called DNTH103)
- What this could lead to
- If it works, this could point toward a new treatment option for multifocal motor neuropathy that reduces the need for immunoglobulin therapy.
- What could go wrong
- This is an early Phase 2 trial with only 36 participants, so results may not apply to everyone. The drug may not prove effective or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIFOCAL MOTOR NEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cinical Study Site
Toronto, Canada
-
Cinical Study Site
Beijing, 100053, China
-
Cinical Study Site
Shanghai, 200031, China
-
Cinical Study Site
Kuala Lumpur, 50586, Malaysia
-
Cinical Study Site
Kuala Lumpur, 59100, Malaysia
-
Cinical Study Site
Permatang Pauh, 13700, Malaysia
-
Cinical Study Site
Sarawak, 93586, Malaysia
-
Cinical Study Site
Daegu, South Korea
-
Cinical Study Site
Alicante, 03010, Spain
-
Cinical Study Site
Barcelona, 08041, Spain
-
Cinical Study Site
Istanbul, 34093, Turkey (Türkiye)
-
Cinical Study Site #2
Seoul, South Korea
-
Clinical Study Site
Scottsdale, Arizona, 85251, United States
-
Clinical Study Site
Los Angeles, California, 90048, United States
-
Clinical Study Site
Bradenton, Florida, 34205, United States
-
Clinical Study Site
Tampa, Florida, 33620, United States
-
Clinical Study Site
Honolulu, Hawaii, 96817, United States
-
Clinical Study Site
Kansas City, Kansas, 66103, United States
-
Clinical Study Site
Cincinnati, Ohio, 45219, United States
-
Clinical Study Site
Columbus, Ohio, 43210, United States
-
Clinical Study Site
Houston, Texas, 77030, United States
-
Clinical Study Site
Beijing, 100730, China
-
Clinical Study Site
Aarhus, 8200, Denmark
-
Clinical Study Site
Copenhagen, 1172, Denmark
-
Clinical Study Site
Marseille, 13005, France
-
Clinical Study Site
Paris, 94000, France
-
Clinical Study Site
Rome, 00189, Italy
-
Clinical Study Site
Kota Kinabalu, 88200, Malaysia
-
Clinical Study Site
Amsterdam, 1105, Netherlands
-
Clinical Study Site
Utrecht, Netherlands
-
Clinical Study Site
Skopje, North Macedonia
-
Clinical Study Site
Bydgoszcz, 85-090, Poland
-
Clinical Study Site
Katowice, 40-689, Poland
-
Clinical Study Site
Krakow, 30-688, Poland
-
Clinical Study Site
Krakow, 31-202, Poland
-
Clinical Study Site
Belgrade, 11000, Serbia
-
Clinical Study Site
Seoul, South Korea
-
Clinical Study Site
Barcelona, 08035, Spain
-
Clinical Study Site
London, England, United Kingdom
-
Clinical Study Site
Oxford, England, United Kingdom
-
Clinical Study Site
Salford, England, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.